A Patient with Advanced Hepatocellular Carcinoma Treated with Sorafenib Tosylate Showed Massive Tumor Lysis with Avoidance of Tumor Lysis syndrome

Satoru Joshita; Kaname Yoshizawa; Kenji Sano; Satoshi Kobayashi; Tomohiro Sekiguchi; Susumu Morita; Atsushi Kamijo; Michiharu Komatsu; Takeji Umemura; Tetsuya Ichijo; Akihiro Matsumoto; Eiji Tanaka

doi:10.2169/internalmedicine.49.3153

CASE REPORTS

A Patient with Advanced Hepatocellular Carcinoma Treated with Sorafenib Tosylate Showed Massive Tumor Lysis with Avoidance of Tumor Lysis syndrome

Satoru Joshita, Kaname Yoshizawa, Kenji Sano, Satoshi Kobayashi, Tomohiro Sekiguchi, Susumu Morita, Atsushi Kamijo, Michiharu Komatsu, Takeji Umemura, Tetsuya Ichijo, Akihiro Matsumoto, Eiji Tanaka

Author information

Satoru Joshita
Department of Medicine, Division of Gastroenterology and Hepatology, Shinshu University School of Medicine
Kaname Yoshizawa
Department of Medicine, Division of Gastroenterology and Hepatology, Shinshu University School of Medicine
Kenji Sano
Department of Laboratory Medicine, Shinshu University Hospital
Satoshi Kobayashi
Department of Medicine, Division of Gastroenterology and Hepatology, Shinshu University School of Medicine
Tomohiro Sekiguchi
Department of Clinical Training Center, Shinshu University Hospital
Susumu Morita
Department of Medicine, Division of Gastroenterology and Hepatology, Shinshu University School of Medicine
Atsushi Kamijo
Department of Medicine, Division of Gastroenterology and Hepatology, Shinshu University School of Medicine
Michiharu Komatsu
Department of Medicine, Division of Gastroenterology and Hepatology, Shinshu University School of Medicine
Takeji Umemura
Department of Medicine, Division of Gastroenterology and Hepatology, Shinshu University School of Medicine
Tetsuya Ichijo
Department of Medicine, Division of Gastroenterology and Hepatology, Shinshu University School of Medicine
Akihiro Matsumoto
Department of Medicine, Division of Gastroenterology and Hepatology, Shinshu University School of Medicine
Eiji Tanaka
Department of Medicine, Division of Gastroenterology and Hepatology, Shinshu University School of Medicine

Keywords: hepatocellular carcinoma, sorafenib, tumor lysis, tumor lysis syndrome

JOURNAL OPEN ACCESS

2010 Volume 49 Issue 11 Pages 991-994

DOI https://doi.org/10.2169/internalmedicine.49.3153

Details

Abstract

A 33-year-old man presented with pain and palsy of the leg in 2008 for treatment of hepatocellular carcinoma with huge distant metastases. The patient's tumors had slowly enlarged despite several treatments. Oral administration of sorafenib at 800 mg/day with careful observation was commenced in 2009. Laboratory investigations on day 7 showed massive tumor lysis. An abdominal CT showed multiple low density areas and tumor markers decreased, indicating extended tumor necrosis. In conclusion, clinicians should bear in mind not only the published adverse effects, but also massive tumor lysis, when treating patients with large tumor burden by sorafenib.

Corresponding author